|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
POTENTIAL FOR INCREASED SERUM LITHIUM LEVELS AND TOXICITY
|
POTENTIAL FOR INCREASED SERUM LITHIUM LEVELS AND TOXICITY
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
POSSIBLE POTENTIATION OF BRADYCARDIA, SINUS ARREST AND AV BLOCK
|
CIMETIDINE INCREASES ITS PLASMA CONCENTRATION AND HENCE BIOAVAILABILITY
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
CO-ADMINISTRATION MAY RESULT IN INCREASED HYPOTENSIVE EFFECT
|
PHENYTOIN ENHANCES THE DRUG METABOLISM HENCE DECREASED SERUM LEVELS HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
ITRACONAZOLE REDUCES THE DRUG METABOLISM HENCE SERUM LEVELS ARE INCREASED
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS CALCIUM CHANNEL BLOCKER , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
ENHANCES THE ABSORPTION OF METFORMIN BY INCREASING PLASMA METFORMIN CMAX AND AUC ; POTENTIAL FOR LOSS OF GLYCEMIC CONTROL
|
ENHANCES THE ABSORPTION OF METFORMIN BY INCREASING PLASMA METFORMIN CMAX AND AUC ; POTENTIAL FOR LOSS OF GLYCEMIC CONTROL
|
FENTANYL ANAESTHESIA IN HIGH DOSES MAY CAUSE SEVERE HYPOTENSION &/OR INCREASED FLUID VOLUME REPLACEMENT WHEN USED IN PATIENTS HAVING NIFEDIPINE & BETABLOCKERS BOTH
|
CALCIUM CHANNEL BLOCKERS MAY POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY & AUTOMATICITY AS WELL AS VASCULAR DILATATION ASSOCIATED WITH ANAESTHETICS
|
CALCIUM CHANNEL BLOCKERS MAY POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY & AUTOMATICITY AS WELL AS VASCULAR DILATATION ASSOCIATED WITH ANAESTHETICS
|
CALCIUM CHANNEL BLOCKERS MAY POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY & AUTOMATICITY AS WELL AS VASCULAR DILATATION ASSOCIATED WITH ANAESTHETICS
|
CALCIUM CHANNEL BLOCKERS MAY POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY & AUTOMATICITY AS WELL AS VASCULAR DILATATION ASSOCIATED WITH ANAESTHETICS
|
CALCIUM CHANNEL BLOCKERS MAY POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY & AUTOMATICITY AS WELL AS VASCULAR DILATATION ASSOCIATED WITH ANAESTHETICS
|
CALCIUM CHANNEL BLOCKERS MAY POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY & AUTOMATICITY AS WELL AS VASCULAR DILATATION ASSOCIATED WITH ANAESTHETICS
|
CALCIUM CHANNEL BLOCKERS MAY POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY & AUTOMATICITY AS WELL AS VASCULAR DILATATION ASSOCIATED WITH ANAESTHETICS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
FLUCONAZOLE INCREASES SERUM PLASMA CONCENTRATION OF THE DRUG
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
GATIFLOXACIN MAY HAVE THE POTENTIAL TO PROLONG THE QT INTERVAL ; CO-ADMINISTRATION WITH DRUGS KNOWN TO PROLONG QT INTERVAL SHOULD BE AVOIDED
|
GATIFLOXACIN MAY HAVE THE POTENTIAL TO PROLONG THE QT INTERVAL ; CO-ADMINISTRATION WITH DRUGS KNOWN TO PROLONG QT INTERVAL SHOULD BE AVOIDED
|
GATIFLOXACIN MAY HAVE THE POTENTIAL TO PROLONG THE QT INTERVAL ; CO-ADMINISTRATION WITH DRUGS KNOWN TO PROLONG QT INTERVAL SHOULD BE AVOIDED
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
CLONIDINE CO-ADMINISTRATION WITH AGENTS KNOWN TO AFFECT SINUS NODE FUNCTION OR A.V. NODAL CONDUCTION LIKE DIGOXIN,CALCIUM CHANNEL BLOCKER & BETABLOCKER MAY CAUSE BRADYCARDIA & A.V. BLOCK
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
CALCIUM CHANNEL BLOCKERS & BETABLOCKERS ARE USUALLY WELL TOLERATED BUT THERE ARE OCCASIONAL REPORTS OF INCREASED CHANCES OF CHF, SEVERE HYPOTENSION, BRADYCARDIA, A.V. BLOCK & EXACERBATION OF ANGINA
|
CALCIUM CHANNEL BLOCKERS & BETABLOCKERS ARE USUALLY WELL TOLERATED BUT THERE ARE OCCASIONAL REPORTS OF INCREASED CHANCES OF CHF, SEVERE HYPOTENSION, BRADYCARDIA, A.V. BLOCK & EXACERBATION OF ANGINA
|
CALCIUM CHANNEL BLOCKERS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
INCREASED RISK OF CARDIOTOXICITY
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|